Glioma is the most common neoplasm of the central nervous system, with the highest mortality rate. The present study was designed to examine the therapeutic effect of Iguratimod (IGU) encapsulated-poly (lactic-co-glycolic acid) PLGA nanoparticles (IGU-PLGA-NPs), which showed inhibition of glioma cells proliferation both in vitro and in vivo. IGU encapsulated in PLGA nanoparticles with an average size of 100-200 nm was prepared using modified double-emulsion (W1/O/W2) method. Cell Counting Kit-8 (CCK-8) analysis of Glioma cancer cells and glioma stem-like cells (GSCs) demonstrated significant inhibition of their growth treated with IGU-PLGA-NPs. IGU-PLGA-NPs inhibit migration in glioma cells as well as tumor sphere formation in GSCs. Treatment with IGU-PLGA-NPs showed a significant decrease in tumor growth through the apoptotic pathway in mice model without any visible organ toxicity and it can successfully cross the blood brain barrier (BBB). Most Importantly, IGU-PLGA-NPs significantly depleted growth of U251 Temozolomide-resistant (U251TMZ-R) cells.

中文翻译：

---

依古拉莫德封装的PLGA-NP可改善神经胶质瘤，神经胶质瘤干样细胞和替莫唑胺抗性神经胶质瘤细胞的治疗效果。

神经胶质瘤是中枢神经系统最常见的肿瘤，死亡率最高。本研究旨在检查伊古拉莫德（IGU）封装的聚乳酸-乙醇酸乙醇共聚物PLGA纳米颗粒（IGU-PLGA-NPs）的治疗效果，该化合物在体外和体内均显示出对神经胶质瘤细胞增殖的抑制作用。使用改良的双乳化（W1 / O / W2）方法制备平均尺寸为100-200 nm的PLGA纳米颗粒中封装的IGU。对神经胶质瘤癌细胞和神经胶质瘤干细胞样细胞（GSC）的Cell Counting Kit-8（CCK-8）分析表明，用IGU-PLGA-NP处理后，它们的生长受到了显着抑制。IGU-PLGA-NP可抑制神经胶质瘤细胞的迁移以及GSC中肿瘤球的形成。使用IGU-PLGA-NP进行的治疗在小鼠模型中通过凋亡途径显着降低了肿瘤的生长，并且没有任何可见的器官毒性，并且可以成功地穿越血脑屏障（BBB）。最重要的是，IGU-PLGA-NPs显着耗尽了耐U251替莫唑胺（U251TMZ-R）细胞的生长。